Condition: Diabetic Foot Ulcer (DFU) · Amnio-Maxx · Sponsor: Royal Biologics
This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs). The study will evaluate Amnio-Maxx® Dual Layer Amnion Patch.
This description comes directly from the study's public registry record.
Nicole Schrecngost · 7246643843 · nschrecengost@serenagroups.com
Greg Cosentino · 5616850299 · greg.cosentino@royalbiologics.com
Always discuss trial participation with your own doctor first.
| Lion Heart Clinical Research | Burbank, California, United States | Recruiting |
| Royal Research South | Miami, Florida, United States | Recruiting |
| Denali Health Atlanta, LLC | Stone Mountain, Georgia, United States | Recruiting |
| SerenaGroup Research Center | Omaha, Nebraska, United States | Recruiting |
| Suffolk Foot and Ankle | East Patchogue, New York, United States | Recruiting |
| Wound Care of Tulsa | Tulsa, Oklahoma, United States | Recruiting |
| VAST Clinical Research Carrollton Foot Center | Carrollton, Texas, United States | Recruiting |
| Elite Foot & Ankle Associates | Spicewood, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07209475